Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129,276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, Bloomquist E, Tang S, Gong Y, Sridhara R, Turcu FR, Chatterjee D, Saritas-Yildirim B, Ghosh S, Philip R, Pathak A, Gao JJ, Amiri-Kordestani L, Pazdur R, Beaver JA. Arora S, et al. Among authors: zhang h. Oncologist. 2021 Jan;26(1):e164-e172. doi: 10.1002/onco.13551. Epub 2020 Oct 20. Oncologist. 2021. PMID: 33017510 Free PMC article. Clinical Trial.
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R. Kim G, et al. Among authors: zhang h. Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17. Clin Cancer Res. 2015. PMID: 26187614 Review.
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, Qiu J, Yu J, Song P, Rahman NA, Chiu HJ, Ricks TK, Rizvi F, Hou S, Wilson W, Abukhdeir AM, Seidman J, Ghosh S, Philip R, Pierce WF, Bhatnagar V, Kluetz PG, Pazdur R, Beaver JA, Amiri-Kordestani L. Gao JJ, et al. Among authors: zhang h. Clin Cancer Res. 2021 Apr 15;27(8):2126-2129. doi: 10.1158/1078-0432.CCR-20-3474. Epub 2020 Nov 13. Clin Cancer Res. 2021. PMID: 33188141
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R. Blumenthal GM, et al. Among authors: zhang l, zhang h. J Clin Oncol. 2015 Mar 20;33(9):1008-14. doi: 10.1200/JCO.2014.59.0489. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667291 Free PMC article.
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.
Chang E, Apolo AB, Bangs R, Chisolm S, Duddalwar V, Efstathiou JA, Goldberg KB, Hansel DE, Kamat AM, Kluetz PG, Lerner SP, Plimack E, Prowell T, Singh H, Suzman D, Yu EY, Zhang H, Beaver JA, Pazdur R, Weinstock C, Galsky MD. Chang E, et al. Among authors: zhang h. Nat Rev Urol. 2022 Jan;19(1):37-46. doi: 10.1038/s41585-021-00505-w. Epub 2021 Sep 10. Nat Rev Urol. 2022. PMID: 34508246 Review.
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, Liu Q, Haber MT, Leutzinger EE, Al-Hakim A, Chen W, Palmby T, Alebachew E, Sridhara R, Ibrahim A, Justice R, Pazdur R. Kluetz PG, et al. Among authors: zhang h. Clin Cancer Res. 2014 Jan 1;20(1):9-14. doi: 10.1158/1078-0432.CCR-13-2665. Epub 2013 Nov 4. Clin Cancer Res. 2014. PMID: 24190979 Clinical Trial.
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Blumenthal GM, et al. Among authors: zhang l, zhang h. JAMA Oncol. 2017 Aug 10;3(8):e171029. doi: 10.1001/jamaoncol.2017.1029. Epub 2017 Aug 10. JAMA Oncol. 2017. PMID: 28617920 Free PMC article.
FDA Approval Summary: Ramucirumab for Gastric Cancer.
Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R. Casak SJ, et al. Among authors: zhang l, zhang h. Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600. Epub 2015 Jun 5. Clin Cancer Res. 2015. PMID: 26048277 Clinical Trial.
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H, Qin N, Yu M, Ma L, Wu Y, Zhang H, Zhang X, Li X, Wang J. Li H, et al. Among authors: zhang h, zhang x. Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33819965 Free PMC article. Chinese.
The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
Li L, Zhang H, Xie Y, Su N, Su S, Zhang X, Cen W. Li L, et al. Among authors: zhang h, zhang x. Comput Math Methods Med. 2022 Feb 25;2022:1475871. doi: 10.1155/2022/1475871. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Nov 1;2023:9789208. doi: 10.1155/2023/9789208 PMID: 35251294 Free PMC article. Retracted. Clinical Trial.
129,276 results
You have reached the last available page of results. Please see the User Guide for more information.